This website uses cookies

Cookies are small text files that can be used by websites to make a user's experience more secure and to analyze traffic to the site. We use cookies for the following purposes:

- Necessary: Cookies are required to access secure areas of the website and to provide important platform notifications. The site cannot function properly without these cookies
- Statistics: Cookies are used to track device information anonymously to better understand how visitors interact with the website.

This notice applies to the following domains:

Emerging Immunotherapy Treatments in Myeloma: CAR T-Cell Therapy and BiTEs

Emerging Immunotherapy Treatments in Myeloma: CAR T-Cell Therapy and BiTEs 

Immunotherapy is an exciting and rapidly growing field in multiple myeloma treatment. Two new immunotherapeutic approaches—chimeric antigen receptor (CAR) T-cell therapy and bispecific T-cell engagers (BiTEs)—are showing encouraging results in clinical trials. CAR-T technology involves using a patient’s own blood cells to recognize and combat multiple myeloma. Likewise, BiTEs are agents that help a patient’s immune system target and fight myeloma cells.

This webinar has been developed to provide an overview of the promise and challenges of these new immunotherapies, along with other essential information that will empower patients and their caregivers as they make future treatment decisions with their care team. 
Ajai Chari, MD
Icahn School of Medicine at Mount Sinai
New York, New York
Edward A. Stadtmauer, MD
University of Pennsylvania
Philadelphia, Pennsylvania

 There is no fee for participating in this webinar.  

Already Registered? Log In Now
Complete this form to register for the webinar.
(* indicates required field)